Cargando…
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial
IMPORTANCE: The potential benefit of novel skeletal muscle anabolic agents to improve physical function in people with sarcopenia and other muscle wasting diseases is unknown. OBJECTIVE: To confirm the safety and efficacy of bimagrumab plus the new standard of care on skeletal muscle mass, strength,...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573681/ https://www.ncbi.nlm.nih.gov/pubmed/33074327 http://dx.doi.org/10.1001/jamanetworkopen.2020.20836 |